Mark Kotter
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Mark Kotter | |
|---|---|
 | |
| Born | Mark Reinhard Kotter Calgary, Canada |
| Nationality | Austrian, Canadian |
| Alma mater | University of Graz, University of Cambridge |
| Known for | cell programming, degenerative cervical myelopathy |
| Scientific career | |
| Fields | Biology, Neurosciences, Medicine |
| Institutions | University of Cambridge, bit.bio, clock.bio, Myelopathy.org, Meatable |
| Website | mark-kotter |
Mark Kotter (born 1971) is a Canadian neurosurgeon, biologist, and entrepreneur. He is the founder and CEO of the biotechnology company bit.bio and the co-founder of the cultured meat company Meatable.
Early life and education
[edit]Kotter was born in Canada and raised in Austria, Germany, and Australia. He studied medicine in Graz and earned a PhD in stem cell biology from the University of Cambridge. He completed postgraduate medical training in Berlin and Vienna and later worked at the Max Planck Institute.[1]
Career
[edit]Kotter has made contributions to the importance of macrophages for brain regeneration,[2] His work on cell programming includes the development of opti-ox (optimized inducible overexpression).[3]
In 2016, Kotter founded it as Elpis Biomed, the company's name later changed to bit.bio to give a clearer indication of its function in cell coding: "bit" refers to the smallest building block in coding, while "bio" refers to the live cells that are being reprogrammed.[4]
In 2019, Kotter co-founded the charity Myelopathy.org to provide information on Degenerative Cervical Myelopathy.[5] In 2018, Kotter co-founded the cultured meat company Meatable with Daan Luining.[6]
References
[edit]- ^ Kotter, M. R.; Pereira, C. F. (2024). "Fast-Forwarding Cellular Reprogramming An Interview with Dr. Mark Kotter". Cellular Reprogramming. 26 (1): 2–7. doi:10.1089/cell.2024.29111.mk. PMID 38381404.
- ^ Kotter, Mark R.; Setzu, Anna; Sim, Fraser J.; Van Rooijen, Nico; Franklin, Robin J.M. (2001). "Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination". Glia. 35 (3): 204–212. doi:10.1002/glia.1085. PMID 11494411.
- ^ Spencer, Diana (August 1, 2023). "bit.bio secures foundational US patent for opti-ox". Drug Discovery World (DDW).
- ^ "Proactive - Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Companies". Proactiveinvestors UK.
- ^ "Cambridge researchers launch charity to tackle 'slow motion spinal cord injury' affecting up to a million UK adults | University of Cambridge". University of Cambridge. May 7, 2019. Retrieved October 20, 2024.
- ^ Brodwin, Erin (September 28, 2018). "A new lab-grown meat startup says it's overcome a key barrier to making meat without slaughter". Business Insider. Archived from the original on October 20, 2024. Retrieved October 20, 2024.